Protalix BioTherapeutics, Inc - תחזית צמיחת רווח נקי למניה לשנה הבאה PLX

The historical EPS forecast for the coming year on the GURU.Markets base chart demonstrates trends where -78.70 indicates the level of this metric for Protalix BioTherapeutics (PLX). The asset relies on the patent protection of the ProCellEx platform and revenues from Fabry disease therapy. A high-margin FCF stream is generated through plant protein licenses. However, geopolitical risks and sanctions complicate the logistics of components from Israel.

The indicator is calculated as the percentage ratio of expected earnings per share for the following year to the current value. This metric assesses the cash flow generation potential to cover liabilities and business development. For Protalix BioTherapeutics (PLX), the low costs of the ProCellEx platform directly determine the future margins of its rare disease therapy. Analyzing the target net income per share growth rate allows for an assessment of market optimism regarding the efficiency of this ecosystem.